Groundwork BioAg

Groundwork BioAgGroundwork BioAg
Groundwork BioAg

Groundwork BioAg

Groundwork BioAg produces highly-effective mycorrhizal inoculants for commercial agriculture to improve crop yields and plant health.

DR 40Speed 492013Active54Mazor, Israel
Rate

About

Groundwork BioAg is an agricultural biotechnology company that develops and produces highly-effective mycorrhizal inoculants for commercial farming. Their Rootella™ products contain concentrated beneficial fungi that significantly enhance soil nutrient uptake in plants, leading to increased crop yields and improved resistance to various stresses. The company aims to make mycorrhizal technology a cornerstone of sustainable and profitable agriculture.
Frequently asked

What does Groundwork BioAg do?

Groundwork BioAg is an agricultural biotechnology company that develops and produces highly-effective mycorrhizal inoculants for commercial farming. Their Rootella™ products contain concentrated beneficial fungi that significantly enhance soil nutrient uptake in plants, leading to increased crop yields and improved resistance to various stresses. The company aims to make mycorrhizal technology a cornerstone of sustainable and profitable agriculture.

What is Groundwork BioAg's valuation?

StartupHub estimates Groundwork BioAg's effective valuation at $122.4M (range $72.5M to $174.0M, 10% confidence), based on comparable companies in the sector.

How much funding has Groundwork BioAg raised?

Groundwork BioAg has raised a total of $29M in funding. The most recent round on record is Series B.

Where is Groundwork BioAg headquartered?

Groundwork BioAg is headquartered in Mazor, Israel.

When was Groundwork BioAg founded?

Groundwork BioAg was founded in 2013.

What industry does Groundwork BioAg operate in?

Groundwork BioAg operates in Agritech, Protein, Mycorrhiza, AgTech, Biotech, Soil Microbiome Restoration.

How many employees does Groundwork BioAg have?

Groundwork BioAg has approximately 54 people on record.

HEADCOUNT
54
DOMAIN RATING
40
Comments

No comments yet. Be the first to share your take.